168 related articles for article (PubMed ID: 7610642)
1. Continued benefit of lovastatin in the treatment of hypercholesterolemia in 36 patients.
Wallace MB; Warren SG; Bates MC; Robinson PA
W V Med J; 1995 Feb; 91(2):50-3. PubMed ID: 7610642
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Schumacher M; Eber B; Silberbauer K; Breier C; Stühlinger W; Schmidt P; Gaul G; Klein W
Acta Med Austriaca; 1992; 19(5):140-4. PubMed ID: 1298143
[TBL] [Abstract][Full Text] [Related]
4. Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia.
Ohri SK; Keane PF; Swift I; Sackier JM; Williamson RC; Thompson GR; Wood CB
Am J Gastroenterol; 1989 Jul; 84(7):740-3. PubMed ID: 2741883
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of low-dose lovastatin in lowering serum cholesterol. Experience with 56 patients.
Bates MC; Warren SG; Grubb S; Chillag S
Arch Intern Med; 1990 Sep; 150(9):1947-50. PubMed ID: 2393325
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Illingworth DR; Stein EA; Mitchel YB; Dujovne CA; Frost PH; Knopp RH; Tun P; Zupkis RV; Greguski RA
Arch Intern Med; 1994 Jul; 154(14):1586-95. PubMed ID: 8031206
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia.
Lukacsko P; Walters EJ; Cullen EI; Niecestro R; Friedhoff LT
Curr Med Res Opin; 2004 Jan; 20(1):13-8. PubMed ID: 14741066
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Farnier M; Bonnefous F; Debbas N; Irvine A
Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
[TBL] [Abstract][Full Text] [Related]
9. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia.
Clauss SB; Holmes KW; Hopkins P; Stein E; Cho M; Tate A; Johnson-Levonas AO; Kwiterovich PO
Pediatrics; 2005 Sep; 116(3):682-8. PubMed ID: 16140708
[TBL] [Abstract][Full Text] [Related]
11. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
[TBL] [Abstract][Full Text] [Related]
12. [Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia].
Prat H; Román O; Pino E
Rev Med Chil; 1999 Mar; 127(3):286-94. PubMed ID: 10436712
[TBL] [Abstract][Full Text] [Related]
13. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
[TBL] [Abstract][Full Text] [Related]
14. [Familial hypercholesterolemia--intensive diet therapy combined with drug therapy].
Stugaard M; Wiig I; Lund H; Ose L; Norseth J
Tidsskr Nor Laegeforen; 1992 Aug; 112(20):2642-6. PubMed ID: 1412289
[TBL] [Abstract][Full Text] [Related]
15. [Influence of lovastatin on serum lipids in patients with primary hyperlipidemia and phenotype IIa and IIB. II. Changes of lipid composition of plasma lipoprotein fractions after lovastatin administration].
Idzior-Waluś B
Przegl Lek; 1992; 49(10):327-33. PubMed ID: 1308286
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
[TBL] [Abstract][Full Text] [Related]
17. [Examination of cortisol and insulin levels in serum of patients with primary hyperlipoproteinemia and phenotype IIa and IIb during lovastatin treatment].
Idzior-Waluś B
Przegl Lek; 1992; 49(11):365-8. PubMed ID: 1306568
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of severe primary hypercholesterolemia with lovastatin (Mevacor). A new therapeutic principle].
Leth A; Munch M; Nielsen B; Dollerup J
Ugeskr Laeger; 1990 Nov; 152(45):3354-7. PubMed ID: 2238228
[TBL] [Abstract][Full Text] [Related]
20. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
